VHL ALLIANCE

VISION
Curing Cancer through VHL

CLINICAL CARE
US VHL Clinical Care Centers: 37
International VHL Clinical Care Centers: 19

MISSION
The VHL Alliance is dedicated to research, education, and support to improve awareness, diagnosis, treatment, and quality of life for those affected by VHL.

VHLA RESOURCES

WHERE DO YOUR VHL ALLIANCE DONATIONS GO?
- 90% of the funds spent on Education & Research
- 3% used to teach and train healthcare professionals
- 7% used for fundraising
- 1% used for management

Fiscal Year 2020

What is VHL?
Von Hippel-Lindau Disease (VHL) is a genetic disease that causes tumors to grow in up to 10 different parts of the body including the brain, spine, eyes, kidneys, pancreas, adrenal glands, inner ears, reproductive tract, liver, and lungs, throughout a patient’s life.

VHL has the same prevalence in all races and ethnicities worldwide

- 200,000 estimated VHL incidences worldwide
- 8 drugs on the market, treating breast and kidney cancer, resulting from VHL research
- Average age of diagnosis is 25
- 1 in 36,000 people in the world have VHL
- 40% of all VHL patients are at risk of developing kidney cancer in their lifetime
- 20% of all VHL patients have a new mutation that has not been inherited from a parent

To make a donation and to learn more about our programs and resources visit us at vhl.org

VHL Alliance, 120 Technology Park, Suite 303, Boston, MA 02132
617-227-5663 x 4
vhl@vhl.org

The VHL Alliance is a 501(c)(3) non-profit organization
Tax ID # 04-3180414

William G. Kaelin, Jr., MD, awarded the Nobel Prize in Medicine for his research on VHL